Global Single-use Assemblies Market Projected to Surge to USD 39.97 Billion by 2030
March 29, 2024 05:35 ET
|
Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Global Single-use Assemblies Market Size, Share & Trends Analysis Report by Product (Bag Assemblies, Filtration Assemblies), Application...
ADC Contract Manufacturing Market projected to reach USD 27.4 Billion by 2030, growing at a CAGR of 14.2% during the forecast period of 2023-2030 - a comprehensive study by MarketDigits
March 05, 2024 08:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, March 05, 2024 (GLOBE NEWSWIRE) -- According to a research report "ADC Contract Manufacturing Market”, by Linker (Cleavable Linker, Non-Cleavable Linkers, and Others), Application...
Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
February 15, 2024 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
BioNTech und DualityBio starten zulassungsrelevante Phase-3-Studie mit Antikörper-Wirkstoff-Konjugat-Kandidat BNT323/DB-1303 bei metastasiertem Brustkrebs
January 22, 2024 06:45 ET
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie mit BNT323/DB-1303 basiert auf positiven Daten zur Sicherheit und Wirksamkeit aus einer Phase-1/2-Studie bei Brustkrebspatientinnen und -patienten mit...
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
January 22, 2024 06:45 ET
|
BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...
Immunotherapy Targeting Mesothelin: A Comprehensive 2023 Pipeline Review
December 14, 2023 05:43 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A groundbreaking review of...
Folate Receptor Alpha Targeted Therapies - Exciting Advancements in Oncological R&D Revealed in Comprehensive Pipeline Review
December 14, 2023 05:28 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This pipeline review...
Anti-CD38 Antibody Pipeline Research Report 2023 Featuring Sorrento Therapeutics, I-MAB Biopharma, Takeda, Hangzhou Sumgen Biotech, Wuhan YZY Biopharma, and Biomunex Pharmaceuticals
November 22, 2023 08:38 ET
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Anti-CD38 antibody - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs
November 17, 2023 08:13 ET
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...